60
Participants
Start Date
January 1, 2026
Primary Completion Date
December 31, 2027
Study Completion Date
January 1, 2028
Suprazygomatic maxillary nerve block (SZMN) with ropivacaine
Participants will receive 15 mg/kg of Tylenol and 4 mg/kg of celecoxib (a nonsteroidal anti-inflammatory (NSAID drug) up to a maximum dose of 200 mg prior to the start of general anesthesia which will consist of gas or intravenous induction (2 mcg/kg fentanyl, 0.5 mg/kg dexamethasone). The SZMN block will be performed using 0.2 ml/kg of 0.25% ropivacaine (local anesthetic), up to a maximum dose of 5 mL. The surgery (tonsillectomy or adenotonsillectomy) will then proceed according to standard of care practices.
Suprazygomatic maxillary nerve block (SZMN) with placebo
Participants will receive 15 mg/kg of Tylenol and 4 mg/kg of celecoxib (a nonsteroidal anti-inflammatory (NSAID drug) up to a maximum dose of 200 mg prior to the start of general anesthesia. which will consist of gas or intravenous induction (2 mcg/kg fentanyl, 0.5 mg/kg dexamethasone). The SZMN block will be performed using 0.2 ml/kg of saline (placebo) up to a maximum dose of 5 mL. The surgery (tonsillectomy or adenotonsillectomy) will then proceed according to standard of care practices.
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
OTHER